ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.50 Average PT from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of analysts have commented on PRQR shares. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. JonesTrading cut their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Bank of America started coverage on ProQR Therapeutics in a report on Thursday, August 20th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of ProQR Therapeutics in a research report on Monday, August 17th.

Insider Transactions at ProQR Therapeutics

In other news, CEO Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average cost of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer owned 300,000 shares of the company’s stock, valued at $522,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bart Filius bought 150,000 shares of ProQR Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the acquisition, the director directly owned 300,000 shares in the company, valued at $516,000. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 600,000 shares of company stock worth $988,500. Insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its position in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Persistent Asset Partners Ltd raised its position in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the period. Diadema Partners LP lifted its stake in shares of ProQR Therapeutics by 6.2% during the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 9,838 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 11,186 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in ProQR Therapeutics by 15.2% in the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 14,549 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Down 7.0%

ProQR Therapeutics stock opened at $2.13 on Friday. ProQR Therapeutics has a 52-week low of $1.33 and a 52-week high of $3.10. The company has a market cap of $224.42 million, a P/E ratio of -4.63 and a beta of 0.07. The business has a 50-day simple moving average of $1.88 and a two-hundred day simple moving average of $1.71.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. Research analysts anticipate that ProQR Therapeutics will post -0.45 EPS for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.